Keyphrases
Glioblastoma
100%
Tumor
67%
Radiation Therapy
41%
Newly Diagnosed Glioblastoma
40%
Proteogenomics
39%
Temozolomide
39%
Glioma
33%
Recurrent Glioblastoma
32%
Glioblastoma multiforme
28%
Neuro-oncology
26%
Glioma Stem Cells
24%
Oncolytic Activity
24%
Zika Virus
24%
Clear Cell Renal Cell Carcinoma (ccRCC)
24%
Phase 1/2 Study
24%
Concurrent Radiation
24%
Disulfiram
24%
Overall Survival
23%
Progression-free Survival
21%
Oncogene
20%
BRAF mutant
18%
Microenvironment
18%
High-grade Glioma
18%
Spatial Transcriptomics
17%
Clinical Trials
16%
CD8+ T Cells
16%
Epigenetic Drivers
16%
Machine Learning
16%
Essential Pathway
16%
CHD4
16%
Photothermal Therapy
16%
Phase II Study
16%
Epigenetics
16%
Doxorubicin
16%
Transcriptomic Characterization
16%
Progression Markers
16%
Tumor Evolution
16%
Brain Tumor
15%
Metabolomics
15%
Tumor Subtype
15%
Genetic Modification
15%
Isocitrate Dehydrogenase 1 (IDH1)
14%
Maximum Tolerated Dose
14%
Lung Cancer
14%
IDH-mutant Glioma
14%
Chromatin Accessibility
13%
Catenin
13%
Precision Medicine
13%
Cancer Types
12%
Phosphorylation
12%
Medicine and Dentistry
Glioblastoma
83%
Neoplasm
66%
Ganglioglioma
39%
Malignant Neoplasm
38%
Neuro-Oncology
25%
Zika Virus
24%
Stem Cell
20%
Proteogenomics
18%
Cytotoxic T-Cell
16%
4 Iodo 2,5 Dimethoxyamphetamine
16%
Clear Cell Renal Cell Carcinoma
16%
Medicine
16%
Intracranial Tumor
15%
Temozolomide
15%
Clinical Trial
14%
Radiation Therapy
14%
Transcriptomics
13%
Immunotherapy
12%
Personalized Medicine
11%
Systemic Therapy
11%
Wnt Signaling
10%
Oncogene
10%
Proteomics
10%
Oligoastrocytoma
9%
Oligodendroglioma
9%
Brain Metastasis
9%
Overall Survival
8%
Clinician
8%
Salvage Therapy
8%
COVID-19
8%
Combined Therapy
8%
Central Nervous System Cancer
8%
Doxorubicin
8%
Patient-Reported Outcome
8%
Functional Status
8%
Brainstem
8%
Hope
8%
Neurological Complication
8%
Interleukin 7
8%
Resting State fMRI
8%
Isocitrate Dehydrogenase
8%
Cell Population
8%
Carcinoma Cell
8%
Cytochrome C Oxidase
8%
Pancreas Cancer
8%
Immune Checkpoint Blockade
8%
Burnout
8%
Biomarker Study
8%
Precision Oncology
8%
Diseases
8%